Abstract:In recent years, studies have demonstrated that vascular endothelial growth factor B (VEGFB) can affect the metabolism of fatty acids and glucose, and it is expected to become a target for the diagnosis and treatment of metabolic diseases such as obesity and diabetes. At present, the specific mechanism that VEGFB regulates lipid and glucose metabolism balance is not completely understood. The present study used systemic VEGFB gene‐knockout mice to investigate the effects of downregulation of the VEGFB gene on lipid metabolism and insulin secretion, and to explore the mechanism of the VEGFB pathway involved in the regulation of glucose and lipid metabolism. The morphological changes in the liver and pancreas of mice after VEGFB gene deletion were observed under a light microscope and a scanning electron microscope, and the effects of VEGFB gene deletion on lipid metabolism and blood glucose balance were detected by a serological technique. The detection indexes included total cholesterol (TC), triglyceride (TG), low‐density lipoprotein cholesterol (LDL‐C) and high‐density lipoprotein cholesterol. Simultaneously, fasting blood glucose, glycosylated hemoglobin A1c (HbA1c), fasting insulin and glucagon were measured. Insulin sensitivity was assessed by using the insulin tolerance tests and glucose tolerance tests, and function of β‐cell islets was evaluated by using the insulin resistance index (HOMA‐IR) and pancreatic β‐cell secretion index (HOMA‐β). Τhe protein expression changes of vascular endothelial growth factor receptor 1 (VEGFR1) and vascular endothelial growth factor receptor 2 (VEGFR2) in mouse islets were detected by western blotting and reverse transcription‐quantitative polymerase chain reaction (RT‐qPCR) after the VEGFB gene was knocked down to analyze the mechanism of VEGFB that may be involved in glucose and lipid metabolism. It was observed that after VEGFB was knocked down, mouse hepatocytes exhibited steatosis and increased secretory vesicles in islet cells. The lipid metabolism indexes such as TG, TC and LDL increased significantly; however, the levels of FBS, postprandial blood glucose and HbA1c decreased, whereas the glucose tolerance increased. Serum insulin secretion increased and HOMA‐IR decreased since VEGFB was knocked down. Western blotting and RT‐qPCR results revealed that the expression levels of VEGFR1 and neuropilin‐1 decreased after the VEGFB gene was knocked down, while the expression levels of VEGFA and VEGFR2 increased. The absence of VEGFB may be involved in the regulation of glucose and lipid metabolism in mice by activating the VEGFA/VEGFR2 signaling pathway. VEGFB is expected to become a new target for the treatment of metabolic diseases such as obesity and diabetes. At present, the mechanism of VEGFB involved in regulating lipid metabolism and glucose metabolism is not completely clear. It was identified that downregulating VEGFB improved lipid metabolism and insulin resistance. The role of VEGFB/VEGFR1 pathway and other family members in regulating glucose and lipid metabolism was detected, which provided a theoretical and experimental basis for VEGFB to affect the regulation of glucose and lipid metabolism balance.

Reducing VEGFB expression regulates the balance of glucose and lipid metabolism in mice via VEGFR1

VEGFB ameliorates insulin resistance in NAFLD via the PI3K/AKT signal pathway

Reducing VEGFB accelerates NAFLD and insulin resistance in mice via inhibiting AMPK signaling pathway

Vascular endothelial growth factor B exerts lipid-lowering effect by activating AMPK via VEGFR1

Knockdown of VEGF-B Improves HFD-induced Insulin Resistance by Enhancing Glucose Uptake in Vascular Endothelial Cells Via the PI3K/Akt Pathway

Reduction in Insulin Uncovers a Novel Effect of VEGFB on Cardiac Substrate Utilization

Regulation of adipose tissue development and energy metabolism by VEGFB isoforms

The Role of Vascular Endothelial Growth Factor-B in Metabolic Homoeostasis: Current Evidence

Metabolic Crosstalk: Molecular Links Between Glycogen and Lipid Metabolism in Obesity

Insulin-like Growth Factor Binding Protein 1 Ameliorates Lipid Accumulation and Inflammation in Nonalcoholic Fatty Liver Disease

Knockdown of VEGFB/VEGFR1 Signaling Promotes White Adipose Tissue Browning and Skeletal Muscle Development

The Role of Vascular Endothelial Growth Factor-B in Metabolic Homeostasis: Current Evidence.

RTEF-1 Attenuates Blood Glucose Levels by Regulating Insulin-Like Growth Factor Binding Protein-1 in the Endothelium

VEGF-B inhibits hyperglycemia- and Macugen-induced retinal apoptosis

Angiopoietin-like Protein 8 (betatrophin) Inhibits Hepatic Gluconeogenesis Through PI3K/Akt Signaling Pathway in Diabetic Mice

Improving High-Fat Diet-Induced Obesity and Fatty Liver by Adipose Tissue Targeted Delivery of Vascular Endothelial Growth Factor-B

VEGF-B prevents chronic hyperglycemia-induced retinal vascular leakage by regulating the CDC42-ZO1/VE-cadherin pathway

Glp-1 Receptor Activation Inhibits Vldl Production And Reverses Hepatic Steatosis By Decreasing Hepatic Lipogenesis In High-Fat-Fed Apoe*3-Leiden Mice

Ablation of Endothelial VEGFR1 Improves Metabolic Dysfunction by Inducing Adipose Tissue Browning

Upregulation of miR-181 a-5 p represses VEGF pathway in high glucose treated human retinal endothelial cells

VEGFC Reduces Glomerular Albumin Permeability and Protects Against Alterations in VEGF Receptor Expression in Diabetic Nephropathy